TNFRSF17 and Miyoshi myopathy: The American Cancer Institute first launched a phase 1 clinical trial of anti-BCMA-CAR-T cell therapy for relapsed/refractory MM (R/RMM) (NCT02215967) demonstrated that BCMA-CAR-T cells are effective against R/RMM, but further optimization is needed to mitigate adverse effects [13, 14].